Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214897721> ?p ?o ?g. }
- W4214897721 endingPage "74" @default.
- W4214897721 startingPage "67" @default.
- W4214897721 abstract "The moderate glucose-lowering effect of sodium glucose co-transporter 2 (SGLT2) inhibitors is unlikely to explain SGLT2 inhibitor-mediated beneficial outcomes, and unravelling the underlying mechanisms is a high priority in the research community. Given the dominant pathophysiologic role of the sympathetic nervous system activation in conditions such as hypertension and perturbed glucose homeostasis, it is pertinent to postulate that SGLT2 inhibitors may exert their beneficial effects at least in part via sympathetic inhibition.SGLT2 inhibitors have shown enormous potential to improve cardiovascular outcomes in patients with type 2 diabetes, and their therapeutic potential is currently being investigated in a range of associated comorbidities such as heart failure and chronic kidney disease. Indeed, recent experimental data in relevant animal models highlight a bidirectional interaction between sympathetic nervous system activation and SGLT2 expression, and this facilitates several of the features associated with SGLT2 inhibition observed in clinical trials including improved glucose metabolism, weight loss, increased diuresis, and lowering of blood pressure. Currently available data highlight the various levels of interaction between the sympathetic nervous system and SGLT2 expression and explores the potential for SGLT2 inhibition as a therapeutic strategy in conditions commonly characterised by sympathetic activation." @default.
- W4214897721 created "2022-03-05" @default.
- W4214897721 creator A5011789921 @default.
- W4214897721 creator A5020466574 @default.
- W4214897721 creator A5023376412 @default.
- W4214897721 creator A5027990979 @default.
- W4214897721 creator A5047370873 @default.
- W4214897721 date "2022-03-01" @default.
- W4214897721 modified "2023-10-13" @default.
- W4214897721 title "Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition" @default.
- W4214897721 cites W1878249378 @default.
- W4214897721 cites W1971122483 @default.
- W4214897721 cites W1974115114 @default.
- W4214897721 cites W1976286624 @default.
- W4214897721 cites W2003797411 @default.
- W4214897721 cites W2008736090 @default.
- W4214897721 cites W2020447893 @default.
- W4214897721 cites W2030311010 @default.
- W4214897721 cites W2031027166 @default.
- W4214897721 cites W2035179445 @default.
- W4214897721 cites W2035868046 @default.
- W4214897721 cites W2048523381 @default.
- W4214897721 cites W2066041574 @default.
- W4214897721 cites W2081795262 @default.
- W4214897721 cites W2082784704 @default.
- W4214897721 cites W2095574383 @default.
- W4214897721 cites W2103714496 @default.
- W4214897721 cites W2123892282 @default.
- W4214897721 cites W2124050105 @default.
- W4214897721 cites W2127413863 @default.
- W4214897721 cites W2138173919 @default.
- W4214897721 cites W2146264128 @default.
- W4214897721 cites W2148897749 @default.
- W4214897721 cites W2149207625 @default.
- W4214897721 cites W2156328907 @default.
- W4214897721 cites W2167245776 @default.
- W4214897721 cites W2171183320 @default.
- W4214897721 cites W2189469504 @default.
- W4214897721 cites W2273304042 @default.
- W4214897721 cites W2295311043 @default.
- W4214897721 cites W2548675393 @default.
- W4214897721 cites W2551481457 @default.
- W4214897721 cites W2555543235 @default.
- W4214897721 cites W2564078202 @default.
- W4214897721 cites W2588337344 @default.
- W4214897721 cites W2592311396 @default.
- W4214897721 cites W2594555601 @default.
- W4214897721 cites W2618856448 @default.
- W4214897721 cites W2624457286 @default.
- W4214897721 cites W2626446274 @default.
- W4214897721 cites W2707117275 @default.
- W4214897721 cites W2750589886 @default.
- W4214897721 cites W2756191633 @default.
- W4214897721 cites W2768862775 @default.
- W4214897721 cites W2792581925 @default.
- W4214897721 cites W2884101530 @default.
- W4214897721 cites W2888671837 @default.
- W4214897721 cites W2898173778 @default.
- W4214897721 cites W2900413769 @default.
- W4214897721 cites W2917271957 @default.
- W4214897721 cites W2939928664 @default.
- W4214897721 cites W2949665037 @default.
- W4214897721 cites W2967895508 @default.
- W4214897721 cites W2969392556 @default.
- W4214897721 cites W2974260792 @default.
- W4214897721 cites W3004108046 @default.
- W4214897721 cites W3015945217 @default.
- W4214897721 cites W3080756519 @default.
- W4214897721 cites W3089283105 @default.
- W4214897721 cites W3106062828 @default.
- W4214897721 cites W3125958190 @default.
- W4214897721 cites W3127131315 @default.
- W4214897721 cites W3169474406 @default.
- W4214897721 cites W3186720525 @default.
- W4214897721 doi "https://doi.org/10.1007/s11906-022-01170-z" @default.
- W4214897721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35235172" @default.
- W4214897721 hasPublicationYear "2022" @default.
- W4214897721 type Work @default.
- W4214897721 citedByCount "9" @default.
- W4214897721 countsByYear W42148977212022 @default.
- W4214897721 countsByYear W42148977212023 @default.
- W4214897721 crossrefType "journal-article" @default.
- W4214897721 hasAuthorship W4214897721A5011789921 @default.
- W4214897721 hasAuthorship W4214897721A5020466574 @default.
- W4214897721 hasAuthorship W4214897721A5023376412 @default.
- W4214897721 hasAuthorship W4214897721A5027990979 @default.
- W4214897721 hasAuthorship W4214897721A5047370873 @default.
- W4214897721 hasBestOaLocation W42148977211 @default.
- W4214897721 hasConcept C126322002 @default.
- W4214897721 hasConcept C134018914 @default.
- W4214897721 hasConcept C2776533406 @default.
- W4214897721 hasConcept C2777180221 @default.
- W4214897721 hasConcept C2777391703 @default.
- W4214897721 hasConcept C2777451236 @default.
- W4214897721 hasConcept C2779547328 @default.
- W4214897721 hasConcept C2779760147 @default.
- W4214897721 hasConcept C2780091579 @default.
- W4214897721 hasConcept C3018667095 @default.